Clinical trial NCT01919827: Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis
Official title: Treatment of Idiopathic Pulmonary Fibrosis With Bone Marrow Derived Mesenchymal Stem Cells
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Idiopathic Pulmonary Fibrosis
Keywords: Idiopathic pulmonary fibrosis
Stem cells
Mesenchymal stem cells
Lead sponsor: Clinica Universidad de Navarra, Universidad de Navarra
Sponsor class: OTHER
First posted: 2013-08-09
Enrollment: 17
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Clinical Trial Phase I, open, multicentric, non randomized, study with escalating doses, to evaluate the safety and feasibility of treatment with mesenchymal stem cells in patients with diagnosis of idiopathic pulmonary fibrosis.

Primary endpoint: The aim is to evaluate the safety and feasibility of the endobronchial administration of mesenchymal autolog stem cells derived from bone marrow (BM-MSC)in patients with mild-to-moderate idiopathic pulmonary fibrosis.

Secondary endpoint:Assess the possible effect of the infusion of BM-MSC in stopping the fall of pulmonary function in patients with mild-to-moderate idiopathic pulmonary fibrosis.


Eligibility criteria: INCLUSION CRITERIA:

1. Capacity for signing informing consent and express the willing to fulfill all the requirements of the study protocol during the study.
2. The patients should be, in the researcher opinion, capable to fulfill all the requirements of the trial.
3. Male or female patients, 30 to 80 years old, inclusive.
4. Diagnosis of idiopathic pulmonary fibrosis according to the following criteria, based on the ATS/ERS Guidelines:

   1. Definite or probable usual interstitial pneumonia confirmed by surgical lung biopsy.
   2. In the absence of surgical lung biopsy, all the following:

   i. High resolution CT (HRCT) showing definite findings for idiopathic pulmonary fibrosis (FPI): bibasal reticular opacities with minimal ground glass opacities.

   ii. Absence of other known causes of FPI including toxicity from drugs, environmental exposure or connective tissue diseases.

   iii. Pulmonary function tests showing ventilatory restrictive pattern and/or impaired gas exchange (FVC and/or DLCO \<90% of predicted)
5. FVC ≥ 50% of predicted value with ratio of FEV1 to FVC ≥ 0.70.
6. DLco (corrected for hemoglobin) ≥ 35% predicted value.
7. Capability of performing a 6 minutes walk test at the time of inclusion.

EXCLUSION CRITERIA:

Any of the following:

1. Current pregnancy or lactation.
2. Findings that are diagnostic of an interstitial pneumonia or restrictive respiratory disease condition other than UIP.
3. Obstructive pulmonary disease defined by FEV1/FVC \< 0,7 or significant emphysema on HRCT.
4. Evidence of sustained improvement in FPI defined by improvement of respiratory function tests before inclusion, observed in \>=2 test over the year prior to inclusion.
5. Active or recent respiratory infection (less than 60 days before inclusion) or history of frequent exacerbations of IPF from an infectious cause (more than 2/year over the last 2 years)
6. Hospitalization in the 60 days prior to inclusion due to acute exacerbation of IPF.
7. Chronic cardiac failure (functional class NYHA III/IV) or left ventricular ejection fraction \< 25%.
8. Chronically receiving corticosteroid more than 10 mg of prednisone or equivalent, immunosuppressors or antifibrotic agents, including pirfenidone, D-penicillamine, colchicine, ciclosporin A, TNF-alpha antagonists, imatinib, IFN-gamma, azathioprine, cyclophosphamide, within the 30 days prior to inclusion.
9. The patient requires hemodialysis, peritoneal dialysis or hemofiltration.
10. History of malignancy, with the exception of skin squamous or basocellular carcinoma or cervix in situ carcinoma treated successfully.
11. History of ethanol abuse within the year prior to inclusion
12. The patient is participating in a clinical trial which includes other drugs or research products within the 28 days prior to baseline assessment.
13. Comorbidities limiting life expectancy to less than 12 months from the baseline assessment.
14. Medical or psychiatric condition serious or active which might interfere with the treatment of study, assessment or protocol fulfillment.
15. Positive test for HBsAg, HCV antibody, syphilis screening essays, or HIV antibody at screening.

Primary outcomes:
measure: Number of participants with adverse side effects.
timeFrame: Up to 12 months
Secondary outcomes:
measure: Efficacy of the infusion of mesenchymal stem cells in stopping the fall in pulmonary function in patients with mild to moderate IPF
timeFrame: Up to 12 months
Other outcomes:
Locations:
city: Pamplona
country: Spain
facility: Servicio de Neumología, Clínica Universidad de Navarra
state: Navarra
city: Salamanca
country: Spain
facility: Servicio de Neumología. Hospital Universitario de Salamanaca
Study officials:
References:
citation: Campo A, Gonzalez-Ruiz JM, Andreu E, Alcaide AB, Ocon MM, De-Torres J, Pueyo J, Cordovilla R, Villaron E, Sanchez-Guijo F, Barrueco M, Nunez-Cordoba J, Prosper F, Zulueta JJ. Endobronchial autologous bone marrow-mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial. ERJ Open Res. 2021 Jun 28;7(2):00773-2020. doi: 10.1183/23120541.00773-2020. eCollection 2021 Apr.